팝업레이어 알림

BeyondDx

  • We create New Paradigm for conquering Cancer

  • We are empowering lives providing deeper intricacies of diseases

  • Unlocking the power of precision medicine through comprehensive cancer profiling

About BeyondDx

BeyondDx is a precision medical company established in August 2023
with the goal of "Comprehensive Cancer Profiling with One Blood."

Our commitment to precision medicine goes beyond conventional approaches.
With UNIQUE iDXGate Solution, we unlock a wealth of invaluable insights,
enabling clinicians to delve deeper into the intricacies of each patient's condition.

view more

Our Strategy

We understand that each patient's journey with cancer is unique. That's why we have developed the groundbreaking iDXGate Solution,
a revolutionary technology that enables accurate analysis of various disease-related factors within a single blood sample.
By harnessing the power of this innovative solution, we empower clinicians to make well-informed decisions and provide patient-specific treatment plans.

Core Technology

iDXGate: UNIQUE BeyondDx Solution; Liquid biopsy-based multi-integrated analysis system

Pipeline

We are accelerating the development of innovative companion diagnostics to provide valuable insights to clinicians with our own platform technology.

view more

Biopharma Service

We collaborate closely with clinicians, researchers, and experts in the field to push the boundaries of what is possible.
We are helping pharmaceutical companies’ breakthrough for cancer therapeutics.

News Room

view more

News

Ministry of SMEs and Startups Hosts Women’s Startup Competition Awards Ceremony – Grand Prize Awarded to Sojin Jung, CEO of BeyondDx

https://www.etoday.co.kr/news/view/2484905Ministry of SMEs and Startups Hosts Women’s Startup Competition Awards Ceremony – Grand Prize Awarded to Sojin Jung, CEO of BeyondDxJuly 4, 2025 | Seoul, South Korea The Ministry of SMEs and Startups (MSS) held the awards ceremony for the 26th Women’s Startup Competition on July 4 at the Nine Tree Premier Rokaus Hotel in Yongsan, Seoul. Out of 1,131 competing teams, a total of 40 teams were selected as award recipients, with Sojin Jung, CEO of BeyondDx, taking home the grand prize (Presidential Award) for her development of an AI-powered algorithm that predicts lung cancer risk using multi-biomarker analysis. The Women’s Startup Competition is Korea’s only national competition for women (and prospective) entrepreneurs, aimed at identifying outstanding startup ideas and promoting technology-based businesses founded by women. This year’s competition recorded a 28:1 competition ratio, underscoring its growing prestige and competitiveness. In alignment with its objective to foster technology-driven startups, 79.5% of participating teams were in sectors such as bio-health and educational services. The high representation in tech-driven fields highlights the increasing role of women in Korea’s innovation economy.Grand Prize Winner: BeyondDx’s AI-based Lung Cancer Diagnostic TechnologyThe grand prize was awarded to Sojin Jung of BeyondDx, who developed a lung cancer diagnostic platform that utilizes a combination algorithm based on blood-derived multi-biomarkers. This technology analyzes multiple cancer-related protein markers through a single blood draw and uses artificial intelligence to predict cancer risk with high accuracy.Other Major Awardees: Excellence Awards: Min-Kyung Cho, CEO of Singing Beatle – for a high-efficiency K-pop global idol training platform Hee-Jin Lim, a prospective entrepreneur – for building a global AI-generated content marketplace Merit Awards: Ui-Jin Yoon, CEO of EJM Company – for an AI-based SaaS system for redevelopment and reconstruction project management Jung-Eun Shin, CEO of Voinosis – for a dementia-prevention AI healthcare service Jo-Young Choi, a prospective founder – for an AI-powered solution that automates the review and preparation of regulatory documents for medical devices Post-Award SupportAll awardees will receive follow-up support programs including commercialization consulting, investment matchmaking, and access to government funding. Additionally, the top 26 teams will secure a spot in the national finals of “Challenge! K-Startup 2025”, scheduled for September.Remarks from GovernmentDeputy Minister Kim Sung-seop of the Ministry of SMEs and Startups stated,  “To ensure women-led startups grow and thrive—from foundation to scale-up and global expansion—MSS will continue to provide customized, full-cycle support through targeted policies.”

2025-07-06

News

BeyondDx to Present Clinical Results of ‘ForeCheck LC’ for Early Lung Cancer Detection at ASCO 2025

https://www.biotimes.co.kr/news/articleView.html?idxno=20498BeyondDx to Present Clinical Results of ‘ForeCheck LC’ for Early Lung Cancer Detection at ASCO 2025Blood biomarker analysis completed within just 150 minutes, offering speed and efficiency Demonstrated sensitivity of 81.9% and specificity of 90.1% in early-stage (Stage 1/2) lung cancer[BioTimes] BeyondDx, a company specializing in multi-integrated analysis solutions, announced on March 27 that it will present clinical study results of its early lung cancer diagnostic in-vitro device, ‘ForeCheck LC’, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago this May.‘ForeCheck LC’ is a blood-based diagnostic device leveraging BeyondDx’s proprietary multi-integrated analysis solution for early lung cancer detection. The device provides optimal diagnostic insights through a simple blood test and employs specific multi-biomarkers and machine learning algorithms to detect lung cancer, even in hard-to-identify Stage 1 and 2 cases. Notably, it can complete blood biomarker analysis and deliver results within just 150 minutes, emphasizing speed and efficiency. At ASCO 2025, BeyondDx will unveil key findings from a clinical study conducted in collaboration with Professor Seok Ki Cho’s team at Seoul National University Bundang Hospital’s Department of Thoracic Surgery. The study evaluated the performance of ‘ForeCheck LC’ in a cohort of approximately 1,800 lung cancer patients (Stages 1–4). The results confirmed a sensitivity of 81.9% and specificity of 90.1% for early-stage (Stage 1/2) lung cancer, underscoring its potential as a blood-based alternative to low-dose computed tomography (LDCT), which has certain limitations. A BeyondDx representative stated, “ForeCheck LC is an innovative early lung cancer diagnostic solution that ensures high compliance among high-risk, asymptomatic individuals. With its rapid, convenient, and cost-effective approach, it presents a promising alternative to conventional imaging tests.” The company plans to initiate pivotal clinical trials in mid-2025 for regulatory approval in South Korea and is actively engaging with potential partners to accelerate market entry.  [BioTimes | Reporter: Jisoo Kim] news@biotimes.co.kr

2025-03-27

News

BeyondDx Signs MOU with Luye Diagnostics for Joint Clinical Research, Marking First Step into the Chinese Market

https://www.thebionews.net/news/articleView.html?idxno=13113BeyondDx Signs MOU with Luye Diagnostics for Joint Clinical Research, Marking First Step into the Chinese MarketBy Kang In-hyo, The Bio | Published: 2025.02.27 06:10 | Updated: 2025.02.27 07:52Collaboration on clinical research for early lung cancer diagnosis and major depressive disorder (MDD) diagnostic pipelines in ChinaClinical research and development of \"ForeCheck LC\" for lung cancer and \"ForeCheck MDD\" for depression in the Chinese market  BeyondDx, a developer of multi-integrated analysis solutions, announced on the 27th that it signed a memorandum of understanding (MOU) with Beijing-based Luye Diagnostics LLC on February 7 for joint clinical research. Under the agreement, the two companies will collaborate on local clinical research and commercialization efforts for BeyondDx’s early lung cancer diagnostic pipeline, ForeCheck LC, and its major depressive disorder diagnostic pipeline, ForeCheck MDD, in China.Luye Diagnostics is a subsidiary of Luye Pharma Group Ltd., a leading global company specializing in oncology and neurology, headquartered in China. The company operates branches in China, Singapore, and the United States, offering genetic diagnostic reagents, companion diagnostics for cancer, and related services. Since 2021, Luye Diagnostics has expanded its business into mental health through Mindfront Health, a subsidiary of Luye Pharma Group, providing comprehensive services from diagnosis to treatment. BeyondDx expects significant synergies with its leading diagnostic pipelines through this partnership. China is actively investing in healthcare infrastructure under its government-led policy, \"Healthy China 2030 (健康中国 2030)\", which includes detailed management guidelines for chronic diseases such as cancer and mental illnesses. The initiative aims to enhance early diagnosis and treatment capabilities. Lung cancer is a major health concern in China, with approximately 1.06 million new cases annually and one of the highest mortality rates globally, driving an urgent need for early detection solutions. Depression is also a growing public health issue, exacerbated by psychological and social factors. Notably, 70% of suicides in China are linked to depression, yet the country faces a severe shortage of hospitals and medical professionals specializing in mental health. This highlights the urgent need for a robust early diagnosis and management system. Jung So-jin, CEO of BeyondDx, stated, “Through our partnership with Luye Diagnostics, we aim to accelerate clinical trials, regulatory approvals, and commercialization in China, laying the groundwork for our global market expansion.”

2025-02-27

view more